Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
At its 13th Annual General Meeting of Shareholders, Samsung Biologics approved all submitted agenda items as originally proposed, including the financial statements with revenue of KRW 3.69T, the appointment of Seung-Hwan Suh as Outside Director and Audit Committee Member, and the approval of the limit on director remuneration.
📊 [Key Disclosure Details & Financial Figures]
- Meeting Type: 13th Annual General Meeting of Shareholders (Meeting Date: March 15, 2024)
- Voting Results by Agenda Item:
- Item 1: Approval of Financial Statements for the 13th Fiscal Year (2023.01.01 ~ 12.31) → Approved as original proposal
- Item 2: Appointment of Outside Director (Seung-Hwan Suh) → Approved as original proposal
- Item 3: Appointment of Audit Committee Member (Seung-Hwan Suh) → Approved as original proposal
- Item 4: Approval of Limit on Remuneration for Directors → Approved as original proposal
- Approved Consolidated Financial Statements for 13th FY (Unit: KRW Million)
- Total Assets: KRW 16,046,197M
- Total Liabilities: KRW 6,215,705M
- Total Equity: KRW 9,830,492M (Capital Stock: KRW 177,935M)
- Revenue: KRW 3,694,589M
- Operating Profit: KRW 1,113,680M
- Net Profit: KRW 857,691M (Earnings Per Share: KRW 12,051)
- Approved Separate Financial Statements for 13th FY (Unit: KRW Million)
- Total Assets: KRW 11,831,261M
- Total Liabilities: KRW 3,592,627M
- Total Equity: KRW 8,238,634M (Capital Stock: KRW 177,935M)
- Revenue: KRW 2,938,756M
- Operating Profit: KRW 1,204,188M
- Net Profit: KRW 945,920M (Earnings Per Share: KRW 13,290)
- Audit Opinion: Unqualified (Both Consolidated and Separate)
- Dividend Information: None (No cash, property, or stock dividends)
- Board Composition Post-Meeting:
- Total Directors: 7 (4 Outside Directors, Outside Director Ratio: 57.14%)
- Audit Committee Members: 3 (All Outside Directors)
- Newly Appointed Executive Details:
- Seung-Hwan Suh (Outside Director and Audit Committee Member, 3-year term, Born June 1956, Former Minister of Land, Infrastructure and Transport and Former President of Yonsei University)
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Board Reorganization and Business Execution Following AGM Approval
This disclosure confirms that all agenda items presented at the Annual General Meeting, including the approval of the FY2023 audited financial statements and board appointments, were officially passed. Verifying the finalized financial statements and updated board composition is essential to understand the settled financial performance for the fiscal year and changes in governance structure. Relevant details can be confirmed in the Annual Report or subsequent corporate governance disclosures.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
